2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Updates on IO in NSCLC: Does Neoadjuvant Durvalumab Add Value to Standard Chemotherapy? Is IO Atezolizumab a Feasible and Safe Addition to SABR?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Millie Das
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Millie Das
81 views
September 22, 2020
Login to view comments.
Click here to Login
Lung
